Cidofovir: Difference between revisions

From IDWiki
No edit summary
()
 
(7 intermediate revisions by the same user not shown)
Line 1: Line 1:
  +
==Background==
* Cytosine nucleotide analogue that inhibits DNA polymerase in [[human herpesviruses]]
 
* Should be given with [[probenecid]] 2 g IV prior to each dose
 
* Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97
 
* Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}}
 
* Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid
 
   
  +
*Acyclic nucleoside phosphonate that competes with cytosine nucleotides to inhibit viral DNA polymerase
[[Category:Antivirals]]
 
 
*Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}}
  +
  +
===Spectrum of Activity===
  +
  +
*Active against essentially all [[:Category:DNA viruses|DNA viruses]], including polyomaviruses ([[BK virus]], [[JC virus]]), [[human papillomavirus]], [[adenovirus]], all of the [[human herpesviruses]], poxviruses (including [[monkeypox virus]] and [[variola virus]])
  +
*Not active against h[[Hepatitis B virus|epatitis B virus]] or [[:Category:RNA viruses|RNA viruses]]
  +
  +
===Pharmacokinetics and Pharmacodynamics===
  +
 
*Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97
  +
*Does not penetrate CSF
  +
  +
==Dosing==
  +
 
*Should be given with [[probenecid]] 2 g IV prior to each dose
  +
  +
==Safety==
  +
 
*Major adverse effect is dose-dependent, irreversible [[Adverse drug reaction::renal tubular necrosis]], which may be prevented by [[probenecid]]
  +
**Contraindicated when creatinine >132 μmol/L, CrCl <55 mL/min, or urine protein ≥100 mg/dL (2+ proteinuria)
  +
*[[Neutropenia]]
  +
*Acute [[iritis]]
  +
  +
[[Category:Acyclic nucleoside phosphonates]]

Latest revision as of 19:14, 14 September 2020

Background

Spectrum of Activity

Pharmacokinetics and Pharmacodynamics

  • Unlike ganciclovir, it does not need phosphorylation by UL97
  • Does not penetrate CSF

Dosing

  • Should be given with probenecid 2 g IV prior to each dose

Safety

  • Major adverse effect is dose-dependent, irreversible renal tubular necrosis, which may be prevented by probenecid
    • Contraindicated when creatinine >132 μmol/L, CrCl <55 mL/min, or urine protein ≥100 mg/dL (2+ proteinuria)
  • Neutropenia
  • Acute iritis